MedTrace Logo

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

NCT01132235 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-05-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of re-treatment with etanercept 50mg subcutaneous injections twice weekly for 12 weeks in subjects who have previously been treated etanercept and efficacy diminished.

Conditions

Interventions

BIOLOGICAL

etanercept

50mgs subcutaneous injections twice a week for 12 weeks

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Florida Academic Dermatology Centers

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01132235 on ClinicalTrials.gov